Research Article

A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection

Table 3

Comparison of medications received during the hospitalization across the comprehensive analysis colchicine and control groups. Hydroxychloroquine doses received and total equivalent prednisone dose received were nonnormally distributed. The Mann–Whitney U test was used to compare the two groups. The χ2 test was used to check for differences in the number of patients receiving steroids, insulin, anticoagulation, enoxaparin, subcutaneous heparin, and direct acting oral anticoagulants (DOACs). Fisher’s exact test to check for differences in the number of patients receiving hydroxychloroquine, oseltamivir, intravenous heparin, and warfarin.

Colchicine group (n = 34)Control group (n = 78) value

Hydroxychloroquine32 (94.1)68 (87.2)0.651
Hydroxychloroquine doses received (median)550.458
Received steroids19 (55.9)47 (60.3)0.665
Total equivalent prednisone dose received (median)101.3177.40.467
Insulin22 (64.7)62 (79.5)0.097
Oseltamivir30 (88.2)68 (87.2)1
Received anticoagulation32 (94.1)74 (94.9)0.871
Enoxaparin28 (82.4)57 (73.1)0.291
DOACs14 (41.2)19 (24.4)0.073
Intravenous heparin1 (2.9)10 (12.8)0.168
Subcutaneous heparin5 (14.7)31 (39.7)0.009
Warfarin01 (1.3)1